Market-based targets for MPT development: Expanding the target product profile

Earlier this year, we wrote a post about Target Product Profiles (TPPs) and the generalized versions that the IMPT developed in 2015 for two MPT product types. As we argue in that post, a product that meets all clinical targets listed in a TPP will not necessarily correlate to its public health impact in the […]

FROM THE PIPELINE | Yaso Therapeutics Yaso-GEL promises to prevent pregnancy and STIs and fill an unmet need in the market

We at Yaso Therapeutics are developing a vaginal gel, called Yaso-GEL, that uses a single proprietary drug to prevent pregnancy as well as genital herpes, gonorrhea, and chlamydia. The gel is mucoadhesive, non-irritating, relatively low-cost, and stable. Yaso-GEL aims to be an MPT that can fill the need for non-hormonal contraceptives and protect women from […]

FROM THE PIPELINE | Monoclonal antibodies as future MPT products

Monoclonal antibodies are engineered proteins derived from a single parent cell and have been used in a diverse range of therapeutic applications due to their versatility and specificity. At Mapp Biopharmaceutical, Inc., we believe monoclonal antibodies are promising candidates for multipurpose prevention technologies (MPTs) when formulated as topical (e.g., films and rings) or injectable products. […]

Young people are leading the charge of the HIV prevention movement

HIV prevention has come to the forefront of youth activism and public health advocacy, as young people aged 15-24 account for 35% of new HIV infections worldwide. In fact, as we work to curb the HIV epidemic, they are the only age group to experience a recent increase in HIV infections. Young people are disproportionately […]

MPT field investments & collaborations are assets for global sexual health

Today, on World Sexual Health Day, we at the IMPT reflect on how to work with partners to improve sexual health across the globe. There are many things that could be done, many different approaches, and many people we can work with towards this goal. Here, at the IMPT, we see multipurpose prevention technologies (MPTs) […]

FROM THE PIPELINE | Taking on a challenge – How an ambitious engineering goal led to an innovative MPT for HIV, HSV, and unintended pregnancy

It all started with the simple realization that women seeking protection against HIV also want to prevent unintended pregnancies. In general, they also prefer a combined method. Then followed the innovation challenge: Engineer a long-acting intravaginal ring that could release two chemically diverse drugs – one for HIV and herpes simplex virus (HSV) prevention, and one […]

Mathematical modelling and its potential to inform MPT development

One of the ongoing challenges in the MPT field is that, because MPT products are not yet commercially available (aside from male and female condoms), we do not have ‘real world’ data to inform product development, introduction, and investment decisions. Given this, MPT product developers, researchers, and funders must grapple with critical questions, such as: […]

Looking ahead: The role of healthcare providers in the success of MPTs

As a healthcare provider, your perspective matters in the movement to advance the field of multipurpose prevention technologies (MPTs). Physicians, nurses, community health workers, pharmacists, and other healthcare providers are critical “gatekeepers” of health products and information with their clients and in their communities, and thus they have a big impact on their patients’ health […]